Adherex Technologies Inc. (TSX:AHX)(AMEX: ADH), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that the Company and the U.S. National Cancer Institute’s (NCI) Division of Cancer Treatment and Diagnosis have executed a Clinical Trial Agreement (CTA) for the evaluation of Adherex’s lead biotechnology compound ADH-1. The agreement provides for the NCI to sponsor non-clinical studies and clinical trials of ADH-1 in a variety of administration schedules and tumor types, both as a single agent and in combination with other anti-cancer agents.
